For health care professionals only

The information contained on this website is intended for use only by health care professionals in the United States. Countries outside of the United States may have different regulatory requirements or medical practices than the United States. Therefore, this information may not be appropriate for use outside of the United States.

Are you a health care professional in the United States?

You will now be leaving the NovoSeven® RT website.

Bibliography

  • Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008;14(5):898-902.

  • Brackmann H-H, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol. 1998;61(suppl 63):18-23.

  • Butler RB, Crudder SO, Riske B, Toal S. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families With a New Diagnosis of Hemophilia. Washington, DC: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2007.

  • Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25˚C stable formulation. Haemophilia. 2007;13(5):527-532.

  • Collins PW, Hirsch S, Baglin TP, et al; for UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-1877.

  • Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010;148(2):183-194.

  • Data on file, Novo Nordisk Inc; Princeton, NJ.

  • FEIBA NF [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2010.

  • Hensyl WR, ed. Stedman’s Medical Dictionary. 25th ed. Baltimore, MD: Williams & Wilkins; 1990.

  • Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-965.

  • Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-575.

  • Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia. 1997;3(3):215-218.

  • Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia. 1998;4(1):689-696.

  • Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven®. Blood Coagul Fibrinolysis. 2000;11(3):239-242.

  • Kessler CM, Acs P, Mariani G. Acquired disorders of coagulation: the immune coagulopathies. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1061-1084.

  • Konkle BA. Clinical approach to the bleeding patient. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1147-1158.

  • Levesque H, Collins P, Baudo F, et al. Acquired haemophilia: descriptive data of the European acquired haemophilia registry (EACH2) [poster PP-WE-604]. J Thromb Haemost. 2009;7(suppl 2):831-832.

  • Luck JV, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12(4):234-245.

  • Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.

  • McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EGD. Factor VII deficiency and the FVII mutation database. Hum Mutat. 2001;17(1):3-17.

  • NovoSeven® RT [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010.

  • Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118(3):689-700.

  • Roberts HR, Escobar MA. Less common congenital disorders of hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:61-79.

  • Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.

  • Venes D, Thomas CL, eds. Taber’s® Cyclopedic Medical Dictionary. 19th ed. Philadelphia, PA: F.A. Davis Company; 2001.

  • World Federation of Hemophilia. Guidelines for the management of hemophilia. http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf. Published 2005. Accessed January 3, 2011.